The first-ever patient in a Phase 3 medical study of LSD has successfully tripped balls
Biopharma firm Mind Medicine announced that they have dosed the first-ever patient in a Phase 3 clinical trial of LSD. The individual tripped on lysergide D-tartrate, an LSD formulation for which the US FDA granted "breakthrough therapy" status in March as a promising treatment for generalized anxiety disorder (GAD).
Of course, Mind Medicine has patented…
Keep reading with a 7-day free trial
Subscribe to Boing Boing to keep reading this post and get 7 days of free access to the full post archives.